The use of cimetidine to reduce dapsone‐dependent methaemoglobinaemia in dermatitis herpetiformis patients.
Tóm tắt
1. We have attempted to reduce dapsone‐dependent methaemoglobinaemia formation in six dermatitis herpetiformis patients stabilised on dapsone by the co‐administration of cimetidine. 2. In comparison with control, i.e. dapsone alone, methaemoglobinaemia due to dapsone fell by 27.3 +/‐ 6.7% and 26.6 +/‐ 5.6% the first and second weeks after commencement of cimetidine administration. The normally cyanotic appearance of the patient on the highest dose of dapsone (350 mg day‐ 1), underwent marked improvement. 3. There was a significant increase in the trough plasma concentration of dapsone (2.8 +/‐ 0.8 x 10(‐5)% dose ml‐1) at day 21 in the presence of cimetidine compared with control (day 7, 1.9 +/‐ 0.6 x 10(‐5)% dose ml‐1, P less than 0.01). During the period of the study, dapsone‐mediated control of the dermatitis herpetiformis in all six patients was unchanged. 4. Trough plasma concentrations of monoacetyl dapsone were significantly increased (P less than 0.05) at day 21 (1.9 +/‐ 1.0 x 10(‐5)% dose ml‐ 1) compared with day 7 (1.6 +/‐ 0.9 x 10(‐5)% dose ml‐1:control). 5. Over a 12 h period, 20.6 +/‐ 8.9% (day 0) of a dose of dapsone was detectable in urine as dapsone hydroxylamine. Significantly less dapsone hydroxylamine was recovered from urine at day 14 (15.0 +/‐ 8.4) in the presence of cimetidine, compared with day 0 (control: P less than 0.05). 6. The co‐administration of cimetidine may be of value in increasing patient tolerance to dapsone, a widely used, effective, but comparatively toxic drug.
Từ khóa
Tài liệu tham khảo
Bruce‐Chwatt L. J., 1982, Essential malariology, 181
DeGowin R. L., 1966, The haemolytic effects of diphenylsulphone (DDS) in normal subjects and in those with glucose 6‐phosphate dehydrogenase deficiency, Bull. W.H.O., 35, 165
Ellard G. A., 1966, Absorption, metabolism and excretion of di(p‐aminophenyl) sulphone (dapsone) and di(p‐aminophenyl) sulphoxide in man, Br. J. clin. Pharmac., 26, 212
Ganer A., 1981, Dapsone induced methaemoglobinaemia and haemolysis in the presence of familial hemoglobinopathy hasharon and familial methaemoglobin reductase deficiency, Is. J. med. Sci., 17, 703
Gordon J. R., 1979, Studies on the urinary metabolites of dapsone in man, Int. J. Leprosy, 47, 681
Grindulis K. A., 1984, Rheumatoid arthritis, the effects of treatment with dapsone on haemoglobin, J. Rheumatol., 11, 776
Grossman S. J., 1988, Role of DDS NOH in dapsone‐induced haemolytic anaemia, J. Pharmac. exp. Ther., 244, 118
Harrison J. H., 1986, Role of aniline metabolites in aniline‐induced hemolytic anemia, J. Pharmac. exp. Ther., 238, 1045
Hornsten P., 1990, The incidence of agranulocytosis during treatment of dermatitis herpetiformis with dapsone as reported in Sweden 1972 through 1988, Arch. Dermatol., 126, 919, 10.1001/archderm.1990.01670310081011
Israili Z. H., 1973, Studies of the metabolism of DDS in man and experimental animals. Formation of N‐hydroxy metabolites, J. Pharmac. exp. Ther., 187, 138
Knodell R. G., 1991, Differential inhibition of individual human liver cytochromes P‐450 by cimetidine, Gastroenterology, 101, 1630, 10.1016/0016-5085(91)90408-D
Uetrecht J. P., 1988, Metabolism of dapsone to a hydroxylamine by human neutrophils and mononuclear cells, J. Pharmac. exp. Ther., 245, 274
Wright J. T., 1984, Cimetidine and dapsone acetylation, Drug. Metab. Disp., 12, 782